Abstract
Purpose
The GONO-FOLFOXIRI regimen demonstrated higher activity and efficacy than FOLFIRI in metastatic colorectal cancer patients. The aim of this study was to determine the maximum tolerated dose of capecitabine, in substitution of 5-fluorouracil, combined with oxaliplatin and irinotecan and to evaluate the pharmacokinetics of the drugs.
Patients and methods
We treated 15 patients with escalating doses of capecitabine (from day 1 to 7) and fixed doses of oxaliplatin (85 mg/m2) plus irinotecan (165 mg/m2) (both administered on day 1), repeated every 2 weeks. Pharmacokinetic analysis was performed on plasma samples collected at the first cycle of treatment.
Results
The maximum tolerated dose of capecitabine resulted 2,000 mg/m2/day, with diarrhea being the only dose-limiting toxicity. Large interpatient variability in the pharmacokinetic parameters of investigated drugs was observed. Results in terms of activity are promising.
Conclusions
At the maximum tolerated dose of capecitabine of 2,000 mg/m2/day the combination is feasible with promising activity and deserves further investigations.
This is a preview of subscription content, log in via an institution to check access.
References
Grothey A, Sargent D, Goldberg RM et al (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209–1214
Falcone A, Masi G, Allegrini G et al (2002) Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 20:4006–4014
Masi G, Allegrini G, Cupini S et al (2004) First line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of phase II study with a simplified biweekly schedule. Ann Oncol 15:1766–1772
Falcone A, Ricci S, Brunetti I et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670–1676
Twelves C, Xeloda Colorectal Cancer Group (2002) Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. Eur J Cancer 38:15–20
Cassidy J, Twelves C, Van Cutsem E et al (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13:566–575
Scheithauer W, Kornek GV, Raderer M et al (2003) Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 21:1307–1312
Ficarra R, Calabro ML, Cutroneo P et al (2002) Validation of a LC method for the analysis of oxaliplatin in a pharmaceutical formulation using an experimental design. J Pharm Biomed Anal 29:1097–1103
Falcone A, Di Paolo A, Masi G et al (2001) Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. J Clin Oncol 19:3456–3462
Di Paolo A, Danesi R, Ciofi L et al (2005) Improved analysis of 5-Fluorouracil and 5, 6-dihydro-5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling. Ther Drug Monit 27:362–368
Koopman M, Antonini NF, Douma J et al (2007) Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370:135–142
Porschen R, Arkenau HT, Kubicka S et al (2007) Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 25:4217–4223
Maroun J, Jonker DJ, Cripps C et al (2007) Capecitabine (X), irinotecan (I) and oxaliplatin (O) as first-line therapy in patients (pts) with advanced or metastatic colorectal cancer (MCRC): phase I study findings. Proc Am Soc Clin Oncol (abstract 4086)
Bajetta E, Celio L, Ferrario E et al (2007) Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. Ann Oncol 18:1810–1816
Rea DW, Nortier JW, Ten Bokkel Huinink WW et al (2005) A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol 16:1123–1132
Krishnamurthi SS, Brell JM, Hoppel CL et al (2008) Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine. Cancer Chemother Pharmacol Apr 15 (Epub ahead of print)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fornaro, L., Masi, G., Bursi, S. et al. A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer. Cancer Chemother Pharmacol 63, 965–969 (2009). https://doi.org/10.1007/s00280-008-0840-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-008-0840-5